HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Hydrochlorothiazide patents expire, and when can generic versions of Hydrochlorothiazide launch?
Hydrochlorothiazide is a drug marketed by Alembic Pharms Ltd, Apotex, Aurobindo Pharma, Chartwell Molecular, Hikma Intl Pharms, Ipca Labs Ltd, Ivax Sub Teva Pharms, Jubilant Cadista, Mylan, Prinston Inc, Sciegen Pharms Inc, Sun Pharm Inds Inc, Unichem, Morton Grove, Roxane, Abc Holding, Accord Hlthcare, Actavis Elizabeth, Alra, Ascot, Aurolife Pharma Llc, Barr, Chartwell Rx, Dava Pharms Inc, Elkins Sinn, Heather, Heritage Pharms, Impax Labs, Inwood Labs, Lannett Co Inc, Leading, Mast Mm, Mylan Pharms Inc, Oxford Pharms, Pvt Form, Solvay, Sun Pharm Industries, Superpharm, Teva, Usl Pharma, Vangard, Warner Chilcott, Watson Labs, Watson Labs Teva, West Ward, Whiteworth Town Plsn, and Pharmeral. and is included in one hundred and ten NDAs.
The generic ingredient in HYDROCHLOROTHIAZIDE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HYDROCHLOROTHIAZIDE?
- What are the global sales for HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for HYDROCHLOROTHIAZIDE?
Summary for HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 47 |
| NDAs: | 110 |
| Finished Product Suppliers / Packagers: | 46 |
| Raw Ingredient (Bulk) Api Vendors: | 134 |
| Clinical Trials: | 383 |
| Patent Applications: | 2,809 |
| Drug Prices: | Drug price information for HYDROCHLOROTHIAZIDE |
| Drug Sales Revenues: | Drug sales revenues for HYDROCHLOROTHIAZIDE |
| What excipients (inactive ingredients) are in HYDROCHLOROTHIAZIDE? | HYDROCHLOROTHIAZIDE excipients list |
| DailyMed Link: | HYDROCHLOROTHIAZIDE at DailyMed |
See drug prices for HYDROCHLOROTHIAZIDE
Recent Clinical Trials for HYDROCHLOROTHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Insel Gruppe AG, University Hospital Bern | Phase 2 |
| University of Bern | Phase 2 |
| University Medical Center Groningen | Phase 3 |
Pharmacology for HYDROCHLOROTHIAZIDE
| Drug Class | Thiazide Diuretic |
| Physiological Effect | Increased Diuresis |
Medical Subject Heading (MeSH) Categories for HYDROCHLOROTHIAZIDE
Anatomical Therapeutic Chemical (ATC) Classes for HYDROCHLOROTHIAZIDE
US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Pharms Inc | HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 040735-003 | Jan 23, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Warner Chilcott | HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 087586-001 | May 3, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Heritage Pharms | HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 085182-003 | May 2, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Aurolife Pharma Llc | HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 085219-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sun Pharm Inds Inc | HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 040810-002 | Mar 27, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
